Recent News

• 09.03.2025 - Atara Biotherapeutics Announces Changes to Its Board of Directors
• 08.11.2025 - Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress
• 07.24.2025 - Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
• 07.14.2025 - Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

Recent Filings

• 09.04.2025 - 8-K Current report
• 08.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.19.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 08.18.2025 - 144 Report of proposed sale of securities
• 08.18.2025 - 144 Report of proposed sale of securities
• 08.11.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.11.2025 - 8-K Current report
• 08.11.2025 - EX-99.1 EX-99.1